CDK9-IN-42

CDK9-IN-42 (Compound L18) (72 h) inhibits proliferation of various hematological tumor cells, with IC₅₀ values of 0.049 μM, 0.071 μM, 0.062 μM, 0.093 μM and 0.175 μM against MV4-11, MOLM-13, THP-1, KG-1, and HL-60 cells, respectively^[1].
CDK9-IN-42 (72 h) inhibits proliferation of various solid tumor cells, with IC₅₀ values of 0.045 μM, 0.166 μM, 0.247 μM and 0.225 μM against HepG2, MCF-7, 22RV1 and A549 cells, respectively^[1].
CDK9-IN-42 (0.1-1 μM, 72 h) exhibits low cytotoxicity against normal human bronchial epithelial cells, with an IC₅₀ of 0.402 μM against BEAS-2B cells^[1].
CDK9-IN-42 shows excellent selectivity for CDK9 over other CDK family members, with IC₅₀ >1 μM for CDK1, CDK4, CDK6, and CDK7^[1].
CDK9-IN-42 (0.1-0.5 μM, 12 h) downregulates protein levels of p-RNAPII-ser2, Mcl-1, c-Myc, CDK9 and Cyclin T1 protein in MV4-11 cells^[1].
CDK9-IN-42 (0.5-1 μM, 12 h) induces apoptosis in MV4-11 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.